Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

ClinicalTrials.gov ID: NCT00743938

Public ClinicalTrials.gov record NCT00743938. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib

Study identification

NCT ID
NCT00743938
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
141 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2009
Primary completion
Jul 31, 2010
Completion
May 31, 2012
Last update posted
Oct 11, 2015

2009 – 2012

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Yale University School Of Medicine New Haven Connecticut 06520
Hematology Oncology, P.C. Stamford Connecticut 06902-3628
Mass General Hospital Boston Massachusetts 02114
Henry Ford Hospital Detroit Michigan 48202-2689
Memorial Sloan Kettering Cancer Center New York New York 10065
Piedmont Hematology Oncology Associates, Pllc Winston-Salem North Carolina 27103
Oregon Health & Science University Portland Oregon 97239
Hema/Oncology Assoc. Of Nepa Dunmore Pennsylvania 18512
Cancer Center Of The Carolinas Greenville South Carolina 29605

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

Recently updated Non Small Cell Lung Cancer trials

Other public records listing Non Small Cell Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.

All Non Small Cell Lung Cancer trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00743938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 11, 2015 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00743938 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →